Inventor · disambiguated record
Jeffery L. Kutok
Also filed as: KUTOK JEFFERY · KUTOK JEFFERY L
11 granted patents·22 pending applications·36 citations·filing 2008–2024
88Inventor score
Files withINFINITY PHARMACEUTICALS INC25SHIPP MARGARET A4DANA FARBER CANCER INST INC3MACDOUGALL JOHN R1
Top patents by PatentIndex Score
33 records- 0194US9775844B2Heterocyclic compounds and uses thereofINFINITY PHARMACEUTICALS INC·Filed 2015·Granted Oct 3, 2017·13 cites·48 claims
- 0292US10675286B2Heterocyclic compounds and uses thereofINFINITY PHARMACEUTICALS INC·Filed 2017·Granted Jun 9, 2020·4 cites·19 claims
- 0391US11541059B2Heterocyclic compounds and uses thereofINFINITY PHARMACEUTICALS INC·Filed 2020·Granted Jan 3, 2023·2 cites·11 claims
- 0486US11147818B2Combination therapiesINFINITY PHARMACEUTICALS INC·Filed 2017·Granted Oct 19, 2021·2 cites·36 claims
- 0586US11110096B2Combination therapiesINFINITY PHARMACEUTICALS INC·Filed 2017·Granted Sep 7, 2021·3 cites·16 claims
- 0683US9206427B2Compositions, kits, and methods for the modulation of immune responses using galectin-1SHIPP MARGARET A·Filed 2008·Granted Dec 8, 2015·4 cites·6 claims
- 0782US8968740B2Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1SHIPP MARGARET A·Filed 2010·Granted Mar 3, 2015·7 cites·14 claims
- 0882US2025319091A1Treatment of cancers using pi3 kinase isoform modulatorsINFINITY PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0979US2025025469A1Combination therapiesINFINITY PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1079US2024293415A1Combination therapiesINFINITY PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1178US2024050437A1Heterocyclic compounds and uses thereofINFINITY PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1278US2024325398A1Combination therapiesINFINITY PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1374US2023364097A1Treatment of cancers using pi3 kinase isoform modulatorsINFINITY PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1472US11723972B2Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1DANA FARBER CANCER INST INC·Filed 2019·Granted Aug 15, 2023·0 cites·8 claims
- 1571US11944631B2Combination therapiesINFINITY PHARMACEUTICALS INC·Filed 2021·Granted Apr 2, 2024·0 cites·20 claims
- 1670US2020338083A1Combination therapiesINFINITY PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1769US2022241287A1Combination therapiesINFINITY PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1868US10456465B2Compositions, kits, and methods for the diagnosis prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1DANA FARBER CANCER INST INC·Filed 2015·Granted Oct 29, 2019·1 cites·22 claims
- 1963US2015025012A1Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signalingINFINITY PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2060US2017348314A1Combination therapiesINFINITY PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2157US2016113932A1Treatment of cancers using pi3 kinase isoform modulatorsINFINITY PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2257US2014377258A1Treatment Of Cancers Using PI3 Kinase Isoform ModulatorsINFINITY PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2356US2015320754A1Combination therapiesINFINITY PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2456US2019212330A1Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-1SHIPP MARGARET A·Filed 2018·Application pending·0 cites
- 2556US2015320755A1Combination therapiesINFINITY PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2652US9939428B2Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-1SHIPP MARGARET A·Filed 2008·Granted Apr 10, 2018·0 cites·16 claims
- 2752US2014120083A1Treatment of cancers using pi3 kinase isoform modulatorsINFINITY PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 2852US2017360795A1Treatment of cancers using pi3 kinase isoform modulatorsINFINITY PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2951US2016022692A1Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitorsINFINITY PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3051US2018002335A1Treatment of cancers using pi3 kinase isoform modulatorsINFINITY PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 3150US2012010230A1Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signalingMACDOUGALL JOHN R·Filed 2011·Application pending·0 cites
- 3249US2016187340A1Compositions, Kits, and Methods for the Modulation of Immune Responses Using Galectin-1DANA FARBER CANCER INST INC·Filed 2015·Application pending·0 cites
- 3343US2015283142A1Treatment of cancers using pi3 kinase isoform modulatorsINFINITY PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jeffery L. Kutok files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →